Mark Rothera
2013 - PTC Therapeutics
In 2013, Mark Rothera earned a total compensation of $2.1M as Chief Commercial Officer at PTC Therapeutics.
Compensation breakdown
| Bonus | $68,200 |
|---|---|
| Non-Equity Incentive Plan | $211,200 |
| Option Awards | $1,364,024 |
| Salary | $300,000 |
| Other | $128,719 |
| Total | $2,072,143 |
Rothera received $1.4M in option awards, accounting for 66% of the total pay in 2013.
Rothera also received $68.2K in bonus, $211.2K in non-equity incentive plan, $300K in salary and $128.7K in other compensation.
Rankings
In 2013, Mark Rothera's compensation ranked 3,799th out of 12,286 executives tracked by ExecPay. In other words, Rothera earned more than 69.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,799 out of 12,286 | 69th |
Division Manufacturing | 1,290 out of 4,612 | 72nd |
Major group Chemicals And Allied Products | 348 out of 1,466 | 76th |
Industry group Drugs | 243 out of 1,160 | 79th |
Industry Pharmaceutical Preparations | 198 out of 890 | 78th |
Source: SEC filing on April 28, 2016.
Rothera's colleagues
We found three more compensation records of executives who worked with Mark Rothera at PTC Therapeutics in 2013.